Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epratuzumab: Additional Phase I/II data

Follow-up data from a Phase I/II trial showed epratuzumab inhibited the activation of

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE